2023-06-02 07:00:00
US green light for Lexicon
The FDA has cleared theInfefa (sotagliflozin) from American biotech Lexicon Pharmaceuticals for the treatment of heart failure in adults, associated with already existing heart failure, type 2 diabetes, chronic kidney disease or other cardiovascular risk factors. In its phase III study, this inhibitor reduced the risk of death and hospitalizations by 33% compared to placebo.
VOS INDICES
source
Galapagos launches a phase II
The Belgian biotech has initiated the phase II study of GLPG3667 in patients with dermatomyositis, a rare autoimmune disease. Carried out on 62 patients suffering from this disease, the trial is scheduled to last 24 weeks, with daily oral intake of the drug candidate. If clinically successful, GLPG3667 might become the first tyrosine kinase inhibitor for the treatment of dermatomyositis.
Fast Track Designation for J&J
The milvexian of Janssen, at branches of NOT A WORDhas just obtained the status Fast Track from the FDA. A designation valid for the three indications for which this drug candidate is currently being evaluated in phase III, namely: ischemic vascular accident, acute coronary syndrome and atrial fibrillation. This compound is an oral factor XIa inhibitor, which the American laboratory is developing in collaboration with Bristol Myers Squibb (BMS).
Selected for you
1685692621
#pipelines #Lexicon #Galapagos
